

Lennart T H Jacobsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9289235/publications.pdf>

Version: 2024-02-01

76
papers

2,814
citations

218592

26
h-index

197736

49
g-index

78
all docs

78
docs citations

78
times ranked

3281
citing authors

#	ARTICLE	IF	CITATIONS
1	Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. <i>Nature Reviews Rheumatology</i> , 2020, 16, 380-390.	3.5	562
2	Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2005-2013.	0.9	187
3	Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 102.	1.6	111
4	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 993-997.	0.5	100
5	Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 105-111.	0.5	97
6	Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1515-1521.	0.5	92
7	Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 17.	1.6	92
8	Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 364-370.	0.5	88
9	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. <i>Arthritis Research and Therapy</i> , 2015, 17, 118.	1.6	77
10	Incidence and prevalence of gout in Western Sweden. <i>Arthritis Research and Therapy</i> , 2016, 18, 164.	1.6	73
11	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.5	72
12	Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2087-2094.	0.5	67
13	Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1838-1842.	0.5	66
14	Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1495-1501.	0.5	63
15	Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. <i>Alzheimer's and Dementia</i> , 2019, 15, 754-763.	0.4	58
16	Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 688-693.	0.5	55
17	Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex. <i>Arthritis Research and Therapy</i> , 2018, 20, 284.	1.6	55
18	Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. <i>Rheumatology</i> , 2015, 54, 1186-1193.	0.9	44

#	ARTICLE	IF	CITATIONS
19	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 218.	1.6	41
20	Validity of gout diagnosis in Swedish primary and secondary care—a validation study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 149.	0.8	34
21	Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 541-548.	0.5	34
22	Body mass index and the risk of giant cell arteritis—results from a prospective study. <i>Rheumatology</i> , 2015, 54, 433-440.	0.9	33
23	Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden. <i>Journal of Rheumatology</i> , 2016, 43, 81-87.	1.0	33
24	A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women. <i>Rheumatology</i> , 2016, 55, 307-314.	0.9	33
25	CD21 ^{low} B cells associate with joint damage in rheumatoid arthritis patients. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12792.	1.3	33
26	Factors associated with initiation and persistence of urate-lowering therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 6.	1.6	32
27	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3229-3236.	0.9	30
28	Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 108.	1.6	29
29	Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. <i>RMD Open</i> , 2016, 2, e000326.	1.8	28
30	Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2017, 44, 981-987.	1.0	23
31	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019, 58, 1649-1654.	0.9	23
32	Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 106.	0.8	21
33	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. <i>RMD Open</i> , 2018, 4, e000655.	1.8	21
34	Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1445-1452.	0.5	21
35	Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects. <i>PLoS ONE</i> , 2014, 9, e113602.	1.1	19
36	Work disability in gout: a population-based case-control study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 399-404.	0.5	19

#	ARTICLE	IF	CITATIONS
37	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Current Therapeutic Research</i> , 2018, 89, 1-6.	0.5	19
38	Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. <i>Rheumatology</i> , 2021, 60, 2725-2734.	0.9	19
39	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictorsâ€™ data from a large national quality register. <i>Arthritis Research and Therapy</i> , 2020, 22, 15.	1.6	19
40	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatmentâ€™ results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020, 59, 1640-1650.	0.9	18
41	Predictors of unacceptable pain with and without low inflammation over 5â€™years in early rheumatoid arthritisâ€™an inception cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 169.	1.6	18
42	Seasonal variations in fatigue in persons with rheumatoid arthritis: a longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 59.	0.8	17
43	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. <i>RMD Open</i> , 2019, 5, e001079.	1.8	17
44	Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. <i>Arthritis Research and Therapy</i> , 2016, 18, 240.	1.6	15
45	The risk of clinically diagnosed gout by serum urate levels: results from 30â€™years follow-up of the MalmÃ¶ Preventive Project cohort in southern Sweden. <i>Arthritis Research and Therapy</i> , 2018, 20, 190.	1.6	14
46	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 3635-3645.	0.9	14
47	Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot. <i>Arthritis Research and Therapy</i> , 2020, 22, 37.	1.6	13
48	Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. <i>Rheumatology</i> , 2018, 57, 1173-1179.	0.9	12
49	The Validity of Gout Diagnosis in Primary Care: Results from a Patient Survey. <i>Journal of Rheumatology</i> , 2019, 46, 1531-1534.	1.0	12
50	The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factorsâ€™30â€™years follow-up of the MalmÃ¶ Preventive Project. <i>Arthritis Research and Therapy</i> , 2020, 22, 244.	1.6	12
51	Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. <i>RMD Open</i> , 2021, 7, e001568.	1.8	12
52	Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 499.	0.8	11
53	Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. <i>RMD Open</i> , 2019, 5, e001053.	1.8	11
54	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. <i>Journal of Rheumatology</i> , 2018, 45, 779-784.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Trends in Gout Hospitalization in Sweden. <i>Journal of Rheumatology</i> , 2018, 45, 145-146.	1.0	8
56	A randomized study comparing regular care with a nurse-led clinic based on tight disease activity control and person-centred care in patients with rheumatoid arthritis with moderate/high disease activity: A 6-month evaluation. <i>Musculoskeletal Care</i> , 2019, 17, 215-225.	0.6	8
57	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
58	Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2021, 40, 1321-1329.	1.0	7
59	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 374-384.	0.6	7
60	Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case-control study based on national registers. <i>Arthritis Research and Therapy</i> , 2016, 18, 16.	1.6	6
61	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e1-e1.	0.5	6
62	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	0.9	6
63	Dual energy CT findings in gout with rapid kilovoltage-switching source with gemstone scintillator detector. <i>BMC Rheumatology</i> , 2020, 4, 7.	0.6	5
64	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1512-1518.	1.0	5
65	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. <i>Rheumatology</i> , 2021, 60, 140-146.	0.9	4
66	Occupational exposure to inorganic dust and risk of gout: a population-based study. <i>RMD Open</i> , 2020, 6, e001178.	1.8	3
67	Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis. <i>Rheumatology</i> , 2021, 60, 1804-1813.	0.9	3
68	Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology International</i> , 2018, 38, 275-282.	1.5	2
69	Association between perinatal factors and future risk for gout: a nested case-control study. <i>Arthritis Research and Therapy</i> , 2022, 24, 60.	1.6	2
70	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. <i>Rheumatology</i> , 2022, 61, 3647-3656.	0.9	2
71	Prevalence and incidence of non-gout crystal arthropathy in southern Sweden. <i>Arthritis Research and Therapy</i> , 2019, 21, 291.	1.6	1
72	Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis: a post-hoc analysis of pooled data from three phase 3 trials with secukinumab. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab009.	0.3	1

#	ARTICLE	IF	CITATIONS
73	SAT0138â€¦PREDICTORS OF CLINICAL EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS: DATA FROM A LARGE OBSERVATIONAL STUDY. , 2019, , .		0
74	Dr. Dehlin, <i>et al</i> reply. Journal of Rheumatology, 2019, 46, 1542.2-1542.	1.0	0
75	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. Rheumatology, 2021, 60, e262-e263.	0.9	0
76	Comment on: Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: results from a national register-based cohort study. Reply. Rheumatology, 2021, , .	0.9	0